Survivin is a negative prognostic marker in medulloblastoma

Neuropathology and Applied Neurobiology

Volumn 31, Issue 4, 2005, Pages 422-428

  Pizem, Joze ^a   Cor A ^b   Zadravec Zaletel, L ^c   Popovic, M ^a  

^a INSTITUTE OF PATHOLOGY   (Slovenia)

^b Medical Faculty   (Slovenia)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

catenin; Medulloblastoma; Survival; Survivin; WNT

Indexed keywords

BETA CATENIN; SURVIVIN; WNT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CEREBELLUM TUMOR; CHILD; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BETA CATENIN; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEDULLOBLASTOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 23044445753     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2005.00664.x     Document Type: Article

References (25)

1. Giangaspero H, Bigner SH, Kleihues P, Pietsch T, Trojanowski JQ. Medulloblastoma. In Tumour of the Nervous System (World Health Organisation Classification of Tumors). Eds P Kleihues, WK Cavenee, Lyon: IARC Press, 2000; 129-37
2. Giordana MT, Schiffer P, Schiffer D. Prognostic factors in medulloblastoma. Child's Nerv Syst 1998; 14: 256-62
3. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004; 5: 209-18
4. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79: 1327-33
5. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001; 34: 207-12
6. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54
7. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to stem cell origin of colon cancer. Cancer Res 2001; 62: 8664-7
8. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin in molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205-9
9. Eberhart CG, Tihan T, Burger PC. Nuclear localisation and mutation of β-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000; 59: 333-7
10. Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, Enomoto T, Shroyer KR. Immunohistochemical localisation of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 2002; 117: 738-44
11. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542-7
12. Pizem J, Cör A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathol 2004; 45: 180-6
13. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ. Survivin in glioblastomas. Arch Pathol Lab Med 2003; 127: 826-33
14. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Antiapoptosis gene, survivin, and prognosis in neuroblastoma. Lancet 1998; 351: 882-3
15. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Differential subcellular localisation of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334-42
16. Sasaki T, Lopes MBS, Hankins GR, Helm GA. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 2002; 104: 105-9
17. Fangusaro RJ, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR, Hayes J, Altura RA. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005; 92: 359-65
18. Bodey B, Bodey V, Siegel SE, Kaiser HE. Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker. In Vivo 2004; 18: 713-8
19. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Abberant regulation of survivin by the RB/E2F familly of proteins. J Biol Chem 2004; 279: 40511-20
20. Mirza A, McGuirk M, Hockenberry Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 2: 2613-22
21. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-57
22. Cogen PH, McDonald JD. Tumor suppressor genes in medulloblastoma. J Neurooncol 1996; 29: 103-12
23. Yokota N, Nishizawa S, Ohta S, Date H, Sugimura H, Namba H, Maekawa M. Role of WNT pathway in medulloblastoma oncogenesis. Int J Cancer 2002; 101: 198-201
24. Koch A, Waha A, Tonn JC, Sörensen N, Berthold F, Wolter M, Reifenberger J, Hartman W, Friedl W, Reifenberger G, Wiestler OT, Pietsch T. Somatic mutations of WNT/WINGLESS signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001; 93: 445-9
25. Altieri DC. Blocking survivin to kill cancer cells. Methods Mol Biol 2003; 223: 533-42